Suppr超能文献

计量吸入器中皮质类固醇溶液生物等效性的关键特征。

Critical characteristics for corticosteroid solution metered dose inhaler bioequivalence.

机构信息

Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, UK.

出版信息

Mol Pharm. 2012 Mar 5;9(3):563-9. doi: 10.1021/mp200415g. Epub 2012 Feb 10.

Abstract

Determining bioequivalence for solution pressurized metered dose inhalers (pMDI) is difficult because the critical characteristics of such products are poorly defined. The aim of this study was to elucidate the non-aerodynamic properties of the emitted aerosol particles from two solution pMDI products that determine their biopharmaceutical differences after deposition. Novel particle capture and analysis techniques were employed to characterize the physicochemical and biopharmaceutical properties of two beclomethasone dipropionate (BDP) products: QVAR and Sanasthmax. The BDP particles emitted from the Sanasthmax inhaler were discernibly different those emitted from QVAR in terms of size (50% larger, less porous), solid state (less crystalline) and dissolution (20-fold slower). When deposited onto the surface of respiratory epithelial cell layers, QVAR delivered ∼50% more BDP across the cell layer in 60 min than Sanasthmax. Biopharmaceutical performance was not attributable to individual particle properties as these were manifold with summative and/or competing effects. The cell culture dissolution-absorption model revealed the net effect of the particle formed on drug disposition and was predictive of human systemic absorption of BDP delivered by the test inhalers. This illustrates the potential of the technique to detect the effect of formulation on the performance of aerosolized particles and contribute to assessment of bioequivalence.

摘要

确定溶液型定量吸入气雾剂(pMDI)的生物等效性具有一定难度,因为此类产品的关键特性尚未明确界定。本研究旨在阐明两种溶液型 pMDI 产品的非空气动力学气溶胶颗粒特性,这些特性决定了产品在沉积后的生物药剂学差异。本研究采用新型颗粒捕获和分析技术,对两种丙酸倍氯米松(BDP)产品(QVAR 和 Sanasthmax)的理化和生物药剂学性质进行了表征。从 Sanasthmax 吸入器中释放出的 BDP 颗粒在大小(大 50%,更疏松)、固体状态(结晶度更低)和溶解速度(慢 20 倍)方面,与 QVAR 明显不同。当沉积在呼吸道上皮细胞层表面时,QVAR 在 60 分钟内穿过细胞层的 BDP 量比 Sanasthmax 多约 50%。生物药剂学性能与个别颗粒特性无关,因为这些特性具有累积和/或竞争效应。细胞培养溶解-吸收模型揭示了颗粒形成对药物分布的净效应,并可预测试验吸入器中 BDP 的人体全身吸收。这说明了该技术具有检测制剂对雾化颗粒性能影响的潜力,并有助于评估生物等效性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验